Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Derivatives -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (201)	5/14/1999 2:12:00 PM
From: sim1	Read Replies (1) \| Respond to of 555

Could this be why? J&J Elects Not to Exercise Option to Co-Promote Norastemizole MARLBOROUGH, Mass., May 14 /PRNewswire/ -- Sepracor Inc. (Nasdaq: SEPR) today announced that Johnson & Johnson (NYSE: JNJ) has elected not to exercise its option to co-promote norastemizole. Sepracor will continue to fund clinical development and marketing of the drug, which is currently in Phase III clinical trials. Norastemizole is a third generation nonsedating antihistamine being developed for seasonal and perennial allergic rhinitis. Under the terms of the agreement between Sepracor and Johnson and Johnson, Sepracor has worldwide rights to all Johnson & Johnson intellectual property covering norastemizole, including the right to reference data from the astemizole New Drug Application (NDA), for Sepracor's norastemizole NDA filing. In exchange, Johnson & Johnson will receive a royalty on Sepracor's product sales. "We understand that Johnson & Johnson's decision not to market the product was based primarily on the fact that the respiratory market is not expected to be a strategic focus for J& J," said Timothy J. Barberich, President and Chief Executive Officer. "We look forward to norastemizole complementing our growing respiratory portfolio, which includes Xopenexa inhalation solution and (R,R)-formoterol." "In conjunction with other prelaunch activities the Company expects to present its scientific data concerning norastemizole at upcoming scientific conferences," said Paul D. Rubin, Executive Vice President, Drug Development and ICE Research. "Our development program is on track for NDA submission by the end of 2000." Sepracor's partnership with Johnson & Johnson on (+)-norcisapride remains unchanged. Sepracor is a specialty pharmaceutical company that develops and commercializes potentially improved versions of widely-prescribed drugs. Referred to as Improved Chemical Entities ("ICE"), Sepracor's ICEa Pharmaceuticals are being developed as proprietary, single-isomer or active- metabolite versions of these leading drugs. ICE Pharmaceuticals are designed to offer meaningful improvements in patient outcome through reduced side effects, increased therapeutic efficacy, improved dosage forms, and in some cases the opportunity for additional indications. This news release contains forward-looking statements that involve risks and uncertainties, including statements with respect to the safety, efficacy and potential benefits of the Company's ICE Pharmaceuticals under development. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the timing of filing and approval of NDAs, the results of the Company's clinical trials with respect to its products under development; the scope of the Company's patent protection with respect to such product candidates; the availability of sufficient funds to continue research and development efforts; and certain other factors that may affect future operating results and are detailed in the Company's periodic reports filed with the Securities and Exchange Commission. Xopenex is a trademark of Sepracor Inc. To receive a copy of this release or recent releases via fax, call Sepracor's automated new fax line at 1-800-758-5804 ext. 780960. /CONTACT: David P. Southwell, Chief Financial Officer, or Jonae R. Barnes, Executive Director, Investor Relations of Sepracor Inc., 508-481-6700/ © Copyright 1999, The Nasdaq Stock Market, Inc. All Rights Reserved. Please read our Disclaimer, Trademarks, and Privacy Statement.